Gilbert Tang, MD, explains how transcatheter tricuspid TEER and total valve replacement options will likely lead to higher tricuspid valve surgical volumes in the years ahead.

Interventional cardiology continues to evolve, driven by rapid advancements in technology. George Dangas, MD, discussed some of the specialty's biggest ongoing trends with Cardiovascular Business. 

Stephen Browning, the FDA's assistant director of hemodynamics and heart failure diagnostics, spoke with Cardiovascular Business about the agency's perspective on AI-enabled cardiovascular devices and many other topics.

Rebecca Hahn, MD, discussed key takeaways from the TRISCEND II trial for the Edwards Lifesciences Evoque TTVR valve and shared additional details related to patient selection and implanting the device.

Michael Reardon, MD, co-principal investigator of the ACURATE IDE trial, discussed updated data on what may have impacted that study's findings.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

FDA Commissioner Robert Califf, MD, talked to Cardiovascular Business about healthcare spending, inconsistent patient outcomes and much more.

Gilbert Tang, MD, surgical director of the structural heart program at the Mount Sinai Health System, discussed a key challenge care teams often encounter during tricuspid valve procedures.